Skip to main content
Log in

Differential Sensitivity of the Species of Candida parapsilosis Sensu Lato Complex Against Statins

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis are human fungal pathogens with clinical importance. The recently reclassified three closely related species have significant variation in virulence, clinical prevalence and susceptibility characteristics to different antifungal compounds. The aim of this study was to investigate the in vitro activity of atorvastatin and fluvastatin against C. metapsilosis, C. orthopsilosis and C. parapsilosis. Susceptibility tests showed that C. parapsilosis was the most sensitive while C. orthopsilosis was the least susceptible species to both drugs. On the basis of the differential sensitivity, we developed a simple, reliable and highly cost-effective plate assay to distinguish these closely related species. Applying this method, 54 isolates belonging to the C. parapsilosis sensu lato complex deposited in Szeged Microbial Collection could be sorted into the three species with 100 % probability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

References

  1. Tavanti A, Davidson AD, Gow NA, Maiden MC, Odds FC. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol. 2005;43(1):284–92. doi:10.1128/JCM.43.1.284-292.2005.

    Article  PubMed  CAS  Google Scholar 

  2. Trofa D, Gacser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008;21(4):606–25. doi:10.1128/CMR.00013-08.

    Article  PubMed  CAS  Google Scholar 

  3. van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol. 2009;35(4):283–309. doi:10.3109/10408410903213393.

    Article  PubMed  Google Scholar 

  4. de Toro M, Torres MJ, Maite R, Aznar J. Characterization of Candida parapsilosis complex isolates. Clin Microbiol Infect. 2010. doi:10.1111/j.1469-0691.2010.03302.x.

    Google Scholar 

  5. Thierry G, Morio F, Le Pape P, Gay-Andrieu F, Barre O, Miegeville M. Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®. Pathol Biol (Paris). 2011;59(1):52–6. doi:10.1016/j.patbio.2010.07.019.

  6. Endo A. A gift from nature: the birth of the statins. Nat Med. 2008;14(10):1050–2. doi:10.1038/nm1008-1050.

    Article  PubMed  CAS  Google Scholar 

  7. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–87.

    Article  PubMed  CAS  Google Scholar 

  8. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett. 2006;262(1):9–13. doi:10.1111/j.1574-6968.2006.00370.x.

    Article  PubMed  CAS  Google Scholar 

  9. Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol. 2002;51(2):105–9.

    PubMed  CAS  Google Scholar 

  10. Song JL, Lyons CN, Holleman S, Oliver BG, White TC. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med Mycol. 2003;41(5):417–25.

    Article  PubMed  CAS  Google Scholar 

  11. Kocsube S, Toth M, Vagvolgyi C, Doczi I, Pesti M, Pocsi I, et al. Occurrence and genetic variability of Candida parapsilosis sensu lato in Hungary. J Med Microbiol. 2007;56(Pt 2):190–5. doi:10.1099/jmm.0.46838-0.

    Article  PubMed  CAS  Google Scholar 

  12. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118. doi:10.1146/annurev.pharmtox.45.120403.095748.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Hungarian National Office for Research and Technology grant: TECH08-A1-IVDMDQ08. AG was supported in part by OTKA NF 84006 and by EMBO Installation Grant 1813. JSZ was supported by TÁMOP 4.2.4.A/2-11-1-2012-0001. This research was realized in the frames of TÁMOP 4.2.4. A/2-11-1-2012-0001 “National Excellence Program—Elaborating and operating an inland student and researcher personal support system convergence program.” The project was subsidized by the European Union and cofinanced by the European Social Fund. Authors are grateful to Dr. Oliver Bader, Dr. Ariana Tavanti and Dr. László Majoros for providing the clinical isolates of Candida species.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Attila Gácser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szenzenstein, J., Gácser, A., Grózer, Z. et al. Differential Sensitivity of the Species of Candida parapsilosis Sensu Lato Complex Against Statins. Mycopathologia 176, 211–217 (2013). https://doi.org/10.1007/s11046-013-9689-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-013-9689-1

Keywords

Navigation